Member

BioResponse, LLC


BioResponse LLC (BR) focuses on the research, development, and manufacturing of patented nanoscale drug formulations. The company’s mission for over 25 years has been its commitment to develop future therapeutic uses of small molecule indoles . BR has developed two patented drug product candidates. Both oral and IV formulations treat acute Central Nervous System (CNS) injury by forming nanoparticles to deliver the lead API. Boulder BioScience (BBS), LLC, the sister company of BR, is focused on the early therapy of brain injury and control of trauma related thrombosis. BBS’s mission is to advance breakthrough science for acute-care indications filling critical, unmet needs in Military Medicine. The drug candidates provide promising new treatments for traumatic brain injury (TBI), Concussion, Blast Injury, and Acute Ischemic Stroke (AIS). Advancement of drug candidates for EMT administered, post-injury use will provide immediate protection of the Blood Brain Barrier, prevent Cerebral Edema, minimize Brain Contusions, and contribute to neurocognitive recovery.

Industries

Biotech
Pharmaceutical / Therapeutics

Nr. of Employees

small (1-50)

BioResponse, LLC


Patents

COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURY

US 12,171,XXX

View Details

METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY

US 11,529,XXX

View Details

METHODS OF TREATING ACUTE CORONARY SYNDROME

US 11,980,XXX

View Details

SELF-EMULSIFYING FORMULATIONS

US 9,918,XXX

View Details

Products

BR9001

The BR9001 oral drug candidate for immediate post-injury TBI treatment consists of liquid-filled, hard-shell capsules delivering the API dissolved in a patented Self-Micro-Emulsifying Drug Delivery (SMEDD) formulation. Once ingested, BR9001 forms a spontaneous nano-scale emulsion for enhanced and rapid absorption, BR9001 delivers the API with peak plasma and brain levels within one hour. BR9001’s clinical use is directed to field and hospital use treating concussive and blast injury in the military. Additionally, BR9001 fills a major unmet need for treatment of the 1.5 Million yearly US cases presenting to ER’s with Moderate-Severe Concussions.

BR4044

The BR-4044 intravenous premix drug candidate for hospital administration utilizes a patented lipid-based combination to fully dissolve the poorly soluble API for treating TBI, Ischemic Stroke, and Acute Myocardial Infarction. With dilution in IV fluid, BR-4044 forms a stable, spontaneous nano-suspension ready for IV administration to patients. Particle analysis of the suspension shows an acceptable polydispersity index with nanometer-scale particle size showing high brain penetration. BR4044 arrests acute neuro-inflammation and hypoxic-ischemic injury by inhibiting the inflammatory Aryl Hydrocarbon Receptor (AhR) response to brain injury. The API inhibits Neutrophil activation and reduces Neutrophil Extra-cellular Trap (NET) formation while preserving neurons and blood brain barrier integrity.

Expertise Areas

  • Neurotrauma / Traumatic Brain Injury
  • Nanoscale Formulations

Key Technologies

  • Oral Self-Emulsifying Drug Delivery
  • Intravenous Nanoemulsion Premixes

Key People

Michael A. Zeligs, M.D.

Co-Founder and CEO


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.